Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia

BMC Psychiatry

Volumn 13, Issue , 2013, Pages

  Potkin, Steven ^a   Bera, Rimal ^b   Zubek, Donna ^c   Lau, Gina ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Community mental health; Depot antipsychotics; Ethnographic; Long acting injectable antipsychotics; Office visit discussions; Patient attitudes; Patient perspectives; Prescriber perspectives; Psychiatrists attitudes; Schizophrenia; Treatment benefits

Indexed keywords

NEUROLEPTIC AGENT; DELAYED RELEASE FORMULATION;

ADULT; ARTICLE; BEHAVIOR MODIFICATION; CAREGIVER; COMORBIDITY; COMPLIANCE (PHYSICAL); CONVERSATION; DOCTOR PATIENT RELATION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEALTH CARE PERSONNEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MEDICATION COMPLIANCE; MOOD DISORDER; NEGATIVE SYNDROME; NURSE PRACTITIONER; PATIENT ATTITUDE; PATIENT COUNSELING; PATIENT PARTICIPATION; POSITIVE SYNDROME; PROFESSIONAL PRACTICE; PSYCHIATRIST; RESTLESS LEGS SYNDROME; SCHIZOPHRENIA; SIDE EFFECT; SOCIAL WORKER; TELEPHONE INTERVIEW; UNSPECIFIED SIDE EFFECT; ADMINISTRATION AND DOSAGE; ATTITUDE TO HEALTH; DELAYED RELEASE FORMULATION; HEALTH PERSONNEL ATTITUDE; MIDDLE AGED; PSYCHIATRY; THERAPEUTIC USE;

ADULT; ANTIPSYCHOTIC AGENTS; ATTITUDE OF HEALTH PERSONNEL; ATTITUDE TO HEALTH; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PHYSICIAN-PATIENT RELATIONS; PSYCHIATRY; SCHIZOPHRENIA;

EID: 84885438433     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-13-261     Document Type: Article

References (33)

1. Olabi B, Ellison-Wright I, McIntosh AM, Wood SJ, Bullmore E, Lawrie SM. Are there progressive brain changes in schizophrenia? A meta-analysis of structural magnetic resonance imaging studies. Biol Psychiatry 2011, 70:88-96. 10.1016/j.biopsych.2011.01.032, 21457946.
2. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, "just the facts" 4. Clinical features and conceptualization. Schizophr Res 2009, 110:1-23. 10.1016/j.schres.2009.03.005, 19328655.
3. Van Haren NE, Hulshoff Pol HE, Schnack HG, Cahn W, Mandl RC, Collins DL, Evans AC, Kahn RS. Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study. Neuropsychopharmacology 2007, 32:2057-2066. 10.1038/sj.npp.1301347, 17327887.
4. Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry 2005, 62:975-983. 10.1001/archpsyc.62.9.975, 16143729.
5. Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 2005, 162:1785-1804. 10.1176/appi.ajp.162.10.1785, 16199825.
6. Emsley R, Nuamah I, Hough D, Gopal S. Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. Schizophr Res 2012, 138:29-34. 10.1016/j.schres.2012.02.030, 22446143.
7. Lieberman JA, Alvir JM, Koreen A, Geisler S, Chakos M, Sheitman B, Woerner M. Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology 1996, 14:13S-21S. 10.1016/0893-133X(95)00200-W, 8866739.
8. Kane JM, Noordsy DL, Cohen LJ, Dufresne RL, Parks J, Saklad S. Importance of early and effective pharmacologic treatment in schizophrenia. Am J Manag Care 2008, S12:S1-S8.
9. Potkin SG, Weiden PJ, Loebel AD, Warrington LE, Watsky EJ, Siu CO. Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol. Int J Neuropsychopharmacol 2009, 12:1233-1248. 10.1017/S1461145709000352, 19419595.
10. Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, Docherty JP. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 2009, 70:1-46.
11. Patel MX, Taylor M, David AS. Antipsychotic long-acting injections: mind the gap. Br J Psychiatry Suppl 2009, 52:S1-S4.
12. Novick D, Haro JM, Suarez D, Vieta E, Naber D. Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. Schizophr Res 2009, 108:223-230. 10.1016/j.schres.2008.11.007, 19070991.
13. Morken G, Widen JH, Grawe RW. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry 2008, 8:32. 10.1186/1471-244X-8-32, 2390550, 18447935.
14. Sun SX, Liu GG, Christensen DB, Fu AZ. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin 2007, 23:2305-2312. 10.1185/030079907X226050, 17697454.
15. Ascher-Svanum H, Zhu B, Faries DE, Furiak NM, Montgomery W. Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia. BMC Res Notes 2009, 2:6. 10.1186/1756-0500-2-6, 2628922, 19138402.
16. Hudson TJ, Owen RR, Thrush CR, Han X, Pyne JM, Thapa P, Sullivan G. A pilot study of barriers to medication adherence in schizophrenia. J Clin Psychiatry 2004, 65:211-216. 10.4088/JCP.v65n0211, 15003075.
17. Peng X, Ascher-Svanum H, Faries D, Conley RR, Schuh KJ. Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia. Clinicoecon Outcomes Res 2011, 3:9-14. 3169974, 21935327.
18. Offord S, Wong B, Mirski D, Baker RA, Lin J. Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral. J Med Econ 2013, 16:231-239. 10.3111/13696998.2012.751025, 23163287.
19. Bera R, Offord S, Zubek D, Lau G, Lin J, Karson C. Evaluation of hospitalization resource usage among Medicaid insured patients with schizophrenia with different treatment duration of long-acting injectable antipsychotic therapy 2012, San Diego, CA, Presented at the U.S. Psychiatric and Mental Health Congress, http://www.psychcongress.com/posters/evaluation-hospitalization-resource-usage-among-medicaid-insured-patients-schizophrenia.
20. Kane JM, Garcia-Ribera C. Clinical guideline recommendations for antipsychotic long-acting injections. Br J Psychiatry Suppl 2009, 52:S63-S67.
21. National Collaborating Centre for Mental Health: Schizophrenia The NICE Guideline on Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care 2010, Updated Edition. Leicester: The British Psychological Society, National Collaborating Centre for Mental Health: Schizophrenia.
22. Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull 2010, 36:94-103. 10.1093/schbul/sbp130, 2800150, 19955388.
23. Paton C, Lelliott P, Harrington M, Okocha C, Sensky T, Duffett R. Patterns of antipsychotic and anticholinergic prescribing for hospital inpatients. J Psychopharmacol 2003, 17:223-229. 10.1177/0269881103017002012, 12870571.
24. Hanssens L, De Hert M, Wampers M, Reginster J-Y, Peuskens J. Pharmacological treatment of ambulatory schizophrenic patients in Belgium. Clin Pract Epidemiol Ment Health 2006, 2:11. 10.1186/1745-0179-2-11, 1481604, 16734909.
25. Xiang YT, Weng YZ, Leung CM, Tang WK, Ungvari GS. Clinical and social correlates with the use of depot antipsychotic drugs in outpatients with schizophrenia in China. Int J Clin Pharmacol Ther 2008, 46:245-251. 10.5414/CPP46245, 18538110.
26. Jablensky A, McGrath J, Herrman H, Castle D, Gureje O, Evans M, Carr V, Morgan V, Korten A, Harvey C. Psychotic disorders in urban areas: an overview of the Study on Low Prevalence Disorders. Aust N Z J Psychiatry 2000, 34:221-236. 10.1080/j.1440-1614.2000.00728.x, 10789527.
27. Waddell L, Taylor M. Attitudes of patients and mental health staff to antipsychotic long-acting injections: systematic review. Br J Psychiatry Suppl 2009, 52:S43-S50.
28. Jaeger M, Rossler W. Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists. Psychiatry Res 2010, 175:58-62. 10.1016/j.psychres.2008.11.003, 20004980.
29. Heres S, Schmitz FS, Leucht S, Pajonk FG. The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol 2007, 22:275-282. 10.1097/YIC.0b013e3280c28424, 17690596.
30. Patel MX, Haddad PM, Chaudhry IB, McLoughlin S, Husain N, David AS. Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years. J Psychopharmacol 2010, 24:1473-1482. 10.1177/0269881109104882, 19477883.
31. Lewis-Beck MS, Bryman A, Futing Liao T. The SAGE Encyclopedia of Social Science Research Methods 2004, Thousand Oaks, CA: SAGE Publications, Inc., Volume 1.
32. Gray R, Spilling R, Burgess D, Newey T. Antipsychotic long-acting injections in clinical practice: medication management and patient choice. Br J Psychiatry Suppl 2009, 52:S51-S56.
33. Patel MX, de Zoysa N, Bernadt M, David A. Depot and oral antipsychotics: patient preferences and attitudes are not the same thing. J Psychopharmacol 2009, 23:789-796. 10.1177/0269881108092124, 18583438.